Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

256.42
+0.94000.37%
Post-market: 256.00-0.4200-0.16%16:25 EDT
Volume:4.22M
Turnover:1.08B
Market Cap:453.19B
PE:72.44
High:258.24
Open:254.17
Low:252.33
Close:255.48
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.12
T/O Rate:0.24%
Dividend:6.83
Dividend Rate:2.66%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-76.36
PE(LYR):108.65

Loading ...

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

MT Newswires Live
·
Jul 28

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), AbbVie (ABBV)

TIPRANKS
·
Jul 28

AbbVie Wraps Up Real-World RINVOQ Study in Psoriatic Arthritis: What Investors Should Watch

TIPRANKS
·
Jul 28

Sarepta Gains After Appointing Former AbbVie Executive Severino as CEO

Reuters
·
Jul 27

Sarepta Names Michael Severino CEO, Succeeding Retiring Doug Ingram

Reuters
·
Jul 27

AbbVie (ABBV) Misses Key Phase 3 Survival Goal For Epcoritamab In DLBCL

Simply Wall St.
·
Jul 25

AbbVie’s ABBV-313 Phase 1 Trial: What Early Safety Work Means for Investors

TIPRANKS
·
Jul 25

AbbVie Advances Nacresertib With Key Drug–Drug Interaction Study

TIPRANKS
·
Jul 25

Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’

Benzinga_recent_news
·
Jul 24

Ema's Chmp: Recommends Granting Marketing Authorisation for Icotyde

THOMSON REUTERS
·
Jul 24

Earning Preview: AbbVie Q2 revenue is expected to increase by 11.54%, and institutional views are bullish

Earnings Agent
·
Jul 24

Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab

Dow Jones
·
Jul 24

Genmab, Abbvie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jul 24

Abbvie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Genmab, Abbvie Clarify Primary Endpoints in Phase 3 Epcore Dlbcl-1 Trial

Reuters
·
Jul 24

Genmab: Clarify Overall Survival (os) was Sole U.S. Primary Endpoint in Phase 3 Epcore(®) Dlbcl-1 Trial and was not Met

THOMSON REUTERS
·
Jul 24

Genmab and Abbvie Provide Clarification on Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (duobody®-cd3xcd20) in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma (dlbcl)

THOMSON REUTERS
·
Jul 24

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GlobeNewswire
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV)

TIPRANKS
·
Jul 23

Abbvie Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23